Analysts Set Humacyte, Inc. (NASDAQ:HUMA) PT at $13.71

Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) has been given an average rating of "Buy" by the eight analysts that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $13.71.

Several research firms have weighed in on HUMA. HC Wainwright restated a "buy" rating and set a $15.00 target price (up from $12.00) on shares of Humacyte in a report on Friday, December 20th. D. Boral Capital reissued a "buy" rating and set a $25.00 price objective on shares of Humacyte in a research note on Friday. Finally, Benchmark restated a "buy" rating on shares of Humacyte in a research report on Thursday, February 27th.

Institutional Trading of Humacyte

Hedge funds and other institutional investors have recently bought and sold shares of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Humacyte by 85.2% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 202,825 shares of the company's stock worth $1,024,000 after purchasing an additional 93,283 shares during the last quarter. Waverly Advisors LLC grew its holdings in Humacyte by 331.9% in the 4th quarter. Waverly Advisors LLC now owns 274,579 shares of the company's stock valued at $1,387,000 after buying an additional 211,009 shares during the period. Woodline Partners LP increased its stake in shares of Humacyte by 235.7% during the 4th quarter. Woodline Partners LP now owns 2,848,802 shares of the company's stock valued at $14,386,000 after acquiring an additional 2,000,268 shares during the last quarter. Squarepoint Ops LLC purchased a new position in shares of Humacyte during the 4th quarter worth about $132,000. Finally, ProShare Advisors LLC boosted its position in shares of Humacyte by 30.4% in the fourth quarter. ProShare Advisors LLC now owns 30,852 shares of the company's stock worth $156,000 after acquiring an additional 7,188 shares during the last quarter. 44.71% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Humacyte Price Performance

Humacyte stock traded up $0.13 during trading hours on Tuesday, hitting $3.09. The stock had a trading volume of 2,613,684 shares, compared to its average volume of 2,290,867. The stock has a market capitalization of $388.90 million, a price-to-earnings ratio of -2.31 and a beta of 1.36. Humacyte has a 1-year low of $2.81 and a 1-year high of $9.97. The stock's fifty day moving average is $4.23 and its two-hundred day moving average is $4.87.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.